Natural Killer (NK) Cell Therapeutics Market Size, Share & Growth Graph by 2034

Table Of Content

Executive Summary

Research Scope & Segmentation

Research Objectives
Limitations & Assumptions
Market Scope & Segmentation
Currency & Pricing Considered

Market Opportunity Assessment

Emerging Regions / Countries
Emerging Companies
Emerging Applications / End Use

Market Trends

Drivers
Market Warning Factors
Latest Macro Economic Indicators
Geopolitical Impact
Technology Factors

Market Assessment

Porters Five Forces Analysis
Value Chain Analysis

Regulatory Framework

North America
Europe
APAC
Middle East and Africa
LATAM

ESG Trends

Global Natural Killer (NK) Cell Therapeutics Market Size Analysis

Global Natural Killer (NK) Cell Therapeutics Market Introduction
By Product
1. Introduction
  1. Product By Value
2. CAR-NK Cell Therapies
  1. By Value
3. NK Cell-directed Antibodies
  1. By Value
By Indication
1. Introduction
  1. Indication By Value
2. Oncology
  1. By Value
3. Infectious Diseases
  1. By Value
4. Autoimmune Diseases
  1. By Value
5. Gastrointestinal Diseases
  1. By Value
6. Other Indications
  1. By Value
By End User
1. Introduction
  1. End User By Value
2. Hospitals & Clinics
  1. By Value
3. Research & Academic Institutes
  1. By Value
4. Other End Users
  1. By Value

North America Market Analysis

Introduction
By Product
1. Introduction
  1. Product By Value
2. CAR-NK Cell Therapies
  1. By Value
3. NK Cell-directed Antibodies
  1. By Value
By Indication
1. Introduction
  1. Indication By Value
2. Oncology
  1. By Value
3. Infectious Diseases
  1. By Value
4. Autoimmune Diseases
  1. By Value
5. Gastrointestinal Diseases
  1. By Value
6. Other Indications
  1. By Value
By End User
1. Introduction
  1. End User By Value
2. Hospitals & Clinics
  1. By Value
3. Research & Academic Institutes
  1. By Value
4. Other End Users
  1. By Value
U.S.
1. By Product
  1. Introduction
    1. Product By Value
  2. CAR-NK Cell Therapies
    1. By Value
  3. NK Cell-directed Antibodies
    1. By Value
2. By Indication
  1. Introduction
    1. Indication By Value
  2. Oncology
    1. By Value
  3. Infectious Diseases
    1. By Value
  4. Autoimmune Diseases
    1. By Value
  5. Gastrointestinal Diseases
    1. By Value
  6. Other Indications
    1. By Value
3. By End User
  1. Introduction
    1. End User By Value
  2. Hospitals & Clinics
    1. By Value
  3. Research & Academic Institutes
    1. By Value
  4. Other End Users
    1. By Value
Canada

Europe Market Analysis

Introduction
By Product
1. Introduction
  1. Product By Value
2. CAR-NK Cell Therapies
  1. By Value
3. NK Cell-directed Antibodies
  1. By Value
By Indication
1. Introduction
  1. Indication By Value
2. Oncology
  1. By Value
3. Infectious Diseases
  1. By Value
4. Autoimmune Diseases
  1. By Value
5. Gastrointestinal Diseases
  1. By Value
6. Other Indications
  1. By Value
By End User
1. Introduction
  1. End User By Value
2. Hospitals & Clinics
  1. By Value
3. Research & Academic Institutes
  1. By Value
4. Other End Users
  1. By Value
U.K.
1. By Product
  1. Introduction
    1. Product By Value
  2. CAR-NK Cell Therapies
    1. By Value
  3. NK Cell-directed Antibodies
    1. By Value
2. By Indication
  1. Introduction
    1. Indication By Value
  2. Oncology
    1. By Value
  3. Infectious Diseases
    1. By Value
  4. Autoimmune Diseases
    1. By Value
  5. Gastrointestinal Diseases
    1. By Value
  6. Other Indications
    1. By Value
3. By End User
  1. Introduction
    1. End User By Value
  2. Hospitals & Clinics
    1. By Value
  3. Research & Academic Institutes
    1. By Value
  4. Other End Users
    1. By Value
Germany
France
Spain
Italy
Russia
Nordic
Benelux
Rest of Europe

APAC Market Analysis

Introduction
By Product
1. Introduction
  1. Product By Value
2. CAR-NK Cell Therapies
  1. By Value
3. NK Cell-directed Antibodies
  1. By Value
By Indication
1. Introduction
  1. Indication By Value
2. Oncology
  1. By Value
3. Infectious Diseases
  1. By Value
4. Autoimmune Diseases
  1. By Value
5. Gastrointestinal Diseases
  1. By Value
6. Other Indications
  1. By Value
By End User
1. Introduction
  1. End User By Value
2. Hospitals & Clinics
  1. By Value
3. Research & Academic Institutes
  1. By Value
4. Other End Users
  1. By Value
China
1. By Product
  1. Introduction
    1. Product By Value
  2. CAR-NK Cell Therapies
    1. By Value
  3. NK Cell-directed Antibodies
    1. By Value
2. By Indication
  1. Introduction
    1. Indication By Value
  2. Oncology
    1. By Value
  3. Infectious Diseases
    1. By Value
  4. Autoimmune Diseases
    1. By Value
  5. Gastrointestinal Diseases
    1. By Value
  6. Other Indications
    1. By Value
3. By End User
  1. Introduction
    1. End User By Value
  2. Hospitals & Clinics
    1. By Value
  3. Research & Academic Institutes
    1. By Value
  4. Other End Users
    1. By Value
Korea
Japan
India
Australia
Taiwan
South East Asia
Rest of Asia-Pacific

Middle East and Africa Market Analysis

Introduction
By Product
1. Introduction
  1. Product By Value
2. CAR-NK Cell Therapies
  1. By Value
3. NK Cell-directed Antibodies
  1. By Value
By Indication
1. Introduction
  1. Indication By Value
2. Oncology
  1. By Value
3. Infectious Diseases
  1. By Value
4. Autoimmune Diseases
  1. By Value
5. Gastrointestinal Diseases
  1. By Value
6. Other Indications
  1. By Value
By End User
1. Introduction
  1. End User By Value
2. Hospitals & Clinics
  1. By Value
3. Research & Academic Institutes
  1. By Value
4. Other End Users
  1. By Value
UAE
1. By Product
  1. Introduction
    1. Product By Value
  2. CAR-NK Cell Therapies
    1. By Value
  3. NK Cell-directed Antibodies
    1. By Value
2. By Indication
  1. Introduction
    1. Indication By Value
  2. Oncology
    1. By Value
  3. Infectious Diseases
    1. By Value
  4. Autoimmune Diseases
    1. By Value
  5. Gastrointestinal Diseases
    1. By Value
  6. Other Indications
    1. By Value
3. By End User
  1. Introduction
    1. End User By Value
  2. Hospitals & Clinics
    1. By Value
  3. Research & Academic Institutes
    1. By Value
  4. Other End Users
    1. By Value
Turkey
Saudi Arabia
South Africa
Egypt
Nigeria
Rest of MEA

LATAM Market Analysis

Introduction
By Product
1. Introduction
  1. Product By Value
2. CAR-NK Cell Therapies
  1. By Value
3. NK Cell-directed Antibodies
  1. By Value
By Indication
1. Introduction
  1. Indication By Value
2. Oncology
  1. By Value
3. Infectious Diseases
  1. By Value
4. Autoimmune Diseases
  1. By Value
5. Gastrointestinal Diseases
  1. By Value
6. Other Indications
  1. By Value
By End User
1. Introduction
  1. End User By Value
2. Hospitals & Clinics
  1. By Value
3. Research & Academic Institutes
  1. By Value
4. Other End Users
  1. By Value
Brazil
1. By Product
  1. Introduction
    1. Product By Value
  2. CAR-NK Cell Therapies
    1. By Value
  3. NK Cell-directed Antibodies
    1. By Value
2. By Indication
  1. Introduction
    1. Indication By Value
  2. Oncology
    1. By Value
  3. Infectious Diseases
    1. By Value
  4. Autoimmune Diseases
    1. By Value
  5. Gastrointestinal Diseases
    1. By Value
  6. Other Indications
    1. By Value
3. By End User
  1. Introduction
    1. End User By Value
  2. Hospitals & Clinics
    1. By Value
  3. Research & Academic Institutes
    1. By Value
  4. Other End Users
    1. By Value
Mexico
Argentina
Chile
Colombia
Rest of LATAM

Competitive Landscape

Natural Killer (NK) Cell Therapeutics Market Share By Players
M&A Agreements & Collaboration Analysis

Market Players Assessment

Fate Therapeutics
1. Overview
2. Business Information
3. Revenue
4. ASP
5. SWOT Analysis
6. Recent Developments
Nkarta Therapeutics
Century Therapeutics
Glycostem Therapeutics
Artiva Biotherapeutics
Affimed N.V.
Innate Pharma
Dragonfly Therapeutics
GT Biopharma
ImmunityBio
Acepodia
Bristol-Myers Squibb
Novartis

Research Methodology

Research Data
1. Secondary Data
  1. Major secondary sources
  2. Key data from secondary sources
2. Primary Data
  1. Key data from primary sources
  2. Breakdown of primaries
3. Secondary And Primary Research
  1. Key industry insights
Market Size Estimation
1. Bottom-Up Approach
2. Top-Down Approach
3. Market Projection
Research Assumptions
1. Assumptions
Limitations
Risk Assessment

Appendix

Discussion Guide
Customization Options
Related Reports

Disclaimer

Get This Report

Our Clients:

Hindustan National Glass & Industries Limited

Table Of Content

Download Free Sample

Mitiksha Koul

Research Associate